Numerof’s 2026 Global Pharma Outlook infographic depicts a pharmaceutical landscape being reshaped by multiple forces, some of which have been on our radar for years, and some new. In addition to the complex story our infographic tells, there is also the impact of a new activist administration.

While it’s tempting to label pressure on drug pricing from payers as the key driver of change, the biggest factor is the Trump administration. Dissatisfied with the impact of the IRA on drug pricing, the new administration has raised the threat of new tariffs and demanded that big pharma companies both reshore their manufacturing and lower their prices to a level consistent with the lowest prices paid by governments in EU markets. Accurate or not, for many U.S. consumers the cost of drugs is a proxy for the spiraling cost of healthcare, and that has energized this administration to create dramatic change. More than ever, the challenge for pharmaceutical manufacturers in 2026 will be to make the strategic and operational changes needed to adapt to these new business demands.

The outlook for the sector is challenging, but certainly not all grim. Aging populations and the growth of chronic disease translates to long term, stable demand for products that can make a difference. And the maturing of new technologies like antibody-drug conjugates (ADCs), cell and gene therapies opens the door to new approaches and new solutions. But the growing cost is a focal point for government payers across the globe. Particularly in the EU, the response has been to raise the bar for market entry. This takes the form of increasing evidentiary requirements, restricted formularies, and growing complexity in rules that govern reimbursement. This is further amplified in the U.S. market by the consolidation of healthcare delivery into fewer, more complex and powerful healthcare systems. Not only do these healthcare corporations bring substantial market clout to the negotiating table, but they are increasing their centralized control over the drugs, devices and tests used across the sprawling inpatient and outpatient facilities they control.

This dynamic is changing who makes purchasing decisions, the criteria used, and the kinds of questions that get asked. Manufacturers continue to adapt their marketing and market access processes to this ongoing trend. We see the need for continued innovation here –in engagement methods and in the way companies structure and support their commercial model. We’re seeing the need for evolution in the use of technology and more sophisticated approaches to major accounts management across sales and commercialization to influence the way in which purchase decisions are made in healthcare. The search for new and effective ways to engage with stakeholders and differentiate products in a crowded field is ongoing.

In addition to these external pressures, the internal pressure of approaching patent cliffs looms large. Over $200B in revenue is on the line by 2028, and these products must be replaced. Big pharma will continue to rely on the pharma ecosystem – emerging companies and research labs – for new products. But they are working against time. Finding a way to accelerate the R&D process and product uptake will be key. Pricing constraints in the U.S and EU have put a spotlight on cost management and heightened attention to processes like evidence development, launch sequencing, and portfolio pricing.

It has been a tumultuous 2025, and the pharmaceutical industry will continue to be in the spotlight in 2026. The challenges are abundant – patent cliffs, margin compression, regulation, and portfolio development. Strategic and operational agility will be key to thriving next year.

Given this outlook, what’s next?  We recommend these key action steps:

At Numerof & Associates, we help pharmaceutical manufacturers achieve these key action steps for success in today’s evolving healthcare landscape. From competitive strategy and ensuring evidence to demonstrate value to commercial model innovation and implementation, we have solutions. Read more about our perspectives and solutions for the pharmaceutical industry and see our case studies.

Need critical insights across the healthcare sector? Check out our 2026 outlook infographics for healthcare delivery, medical devices and diagnostics, and payers.